SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

STMicroelectronics NV is a global semiconductor company, which engages in the business of designing, developing, manufacturing, and marketing products used in a wide variety of applications for automotive, industrial, personal electronics and communications equipment, computers, and peripherals. It operates through the following segments: Automotive and Discrete Group (ADG), Analog, MEMS, and Sensors Group (AMS), Microcontrollers and Digital ICs Group (MDG), and Others. The ADG segment includes dedicated automotive integrated circuits and discrete and power transistor products. The AMS segment offers analog, smart power, MEMS sensors and actuators, and optical sensing solutions. The MDG segment focuses on general-purpose microcontrollers and microprocessors, connected security products, memories, and RF and communications products. The Others segment is involved in sales assembly services and other revenues. The company was founded in June 1987 and is headquartered in Plan-Les-Ouates, Switzerland.

ST Microelectronics - New York Shares

STMicroelectronics NV

STMicroelectronics is trending due to a series of news announcements, including new smart power components leveraging GaN technology and advancements in silicon photonics for AI data centers. The community is also discussing the company's AI solutions for industrial, consumer, and automotive applications. Some investors are concerned about the share price decline despite the bullish news, while others highlight the share repurchase program and potential for a short squeeze.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as the community discusses its potential to lead in AI, particularly after positive reviews for its Gemini 3 model and news that Meta may use Google's TPUs. Some are speculating about the implications for competitors like NVDA and OpenAI, while others point to GOOGL's attractive valuation relative to its growth potential and peers.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as discussions around its AI capabilities intensify, particularly with comparisons to competitors like NVDA and MSFT. The community is debating whether GOOG is winning the AI race, highlighting its TPU technology and potential market share gains. Additionally, analyst commentary and price target updates are contributing to the increased interest in the stock.

shark raptor rocket launcher

SRRL is trending as traders discuss its price action, pointing to steady momentum and clean structure. The community highlights the potential for a significant move, watching for signs of increasing volume and sustained trendline support. Conversations also mention where to buy SRRL, indicating increased interest in the cryptocurrency.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is trending due to its inclusion in the S&P 500, sparking significant discussion about its valuation and future trajectory. While some traders are capitalizing on short-term swings, others are debating whether the stock is overbought or poised for further gains in the memory supercycle. Community members are actively analyzing technical indicators and considering both long and short positions.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr Inc. is trending due to the board halting buyout discussions over financing concerns regarding the $18/share take-private bid from major shareholders, leading to community speculation about a potential hostile takeover and the motives of involved parties. Discussions include insider selling activity and the possibility of other potential buyers emerging, as well as the company's intrinsic value.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets (SSB) is trending with community members highlighting its disciplined chart structure, calm price flow, and balanced candles. Traders are closely watching for signs of accumulation and potential breakouts, emphasizing the importance of patience and composure in trading SSB. There's also discussion around a Litecoin migration in the future.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending as community members discuss its potential in the AI data center space, highlighting its power capacity and low market capitalization. The stock's high trading range and recent increase in volume are also sparking interest, with some suggesting a potential rally. Bullish sentiment is growing due to shifts into AI and GPU compute hosting.

Quantum Resistant Ledger is a cryptocurrency based on the Python programming language, aimed at combating future attacks by quantum computers. This cryptocurrency is the brainchild of Peter Waterland who realised that Bitcoin, Ethereum, and other such cryptocurrencies have no protection against future technology. It claims to be a “future-proof” cryptocurrency which enables transactions and decentralized communication while providing protection against classical as well as quantum computer attacks.  The Quantum Resistant Ledger company was founded by Peter Waterland, who found that Bitcoin, as well as Ethereum signatures are susceptible to attacks by powerful quantum computers. His research on quantum computers and signature programs let to the development of this new cryptocurrency, designed to be resistant to the present classical attacks as well as any future quantum computer attacks. Their team is made up of a diverse range of members spread out across the world, including developers (core, blockchain, mobile developers, etc.), analysts, advisors, marketing managers, designers and more.  Quantum Resistant Ledger is the first ever cryptocurrency and the only one in existence as of August 2018, to consider the threat that the future technology of quantum computing poses to cryptocurrencies and their working. It uses a technology specifically designed for post-quantum security, called XMSS, which makes it secure against powerful quantum computers even while using a Proof-of-Stake consensus mechanism. Security against cyber-attacks is a very serious concern in this digital age, especially when you have digital assets whose loss is likely to lead you to bankruptcy.  QRL is the first blockchain technology that provides durability and stability through resistance to quantum computer attacks. The encryption methods used by modern blockchains can become vulnerable to quantum computers over the next ten years. QRL tries to create a blockchain with long-term stability. By using blockchain technology, the QRL platform creates a “ledger” that generates hashes in such a way that it is virtually impenetrable to any type of computer attack.

Quantum Resistant Ledger 

Quantum Resistant Ledger ($QRL) is trending due to renewed interest in quantum computing and its potential impact on blockchain security; recent quantum breakthroughs have investors considering "quantum hedges." The community highlights QRL's quantum-resistant design since 2018, positioning it as a safe haven against future quantum threats to non-resistant cryptocurrencies like Bitcoin and Ethereum, despite limited exchange listings.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending amid optimism in the lithium sector, driven by forecasts of a supply deficit in 2026 and rising lithium prices, sparking community discussion about potential short squeezes and target prices. Despite positive sentiment, some traders point out potential risks such as insider selling, missing construction approvals, and China's influence on lithium prices. Overall, the community is weighing the potential for significant gains against concerns of overvaluation and market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Highbridge Capital Management LLC Acquires New Stake in Achieve Life Sciences, Inc. $ACHV

Highbridge Capital Management LLC acquired a new stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) in the second quarter, according to the company in its most recent filing...

What is Zacks Small Cap's Estimate for ACHV FY2025 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Equities researchers at Zacks Small Cap cut their FY2025 earnings per share estimates for Achieve Life Sciences in a report issued on Monday...

Achieve Life Sciences, Inc. $ACHV Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. boosted its stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) by 443.7% in the second quarter, according to its most recent filing with the Securities...

Achieve Life Sciences (NASDAQ:ACHV) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the...

Shares of Achieve Life Sciences, Inc. (ACHV) soared 32% on Friday afternoon after the company said that the U.S. Food and Drug Administration (FDA) awarded the company a Commissioner's National Priority Voucher (CNPV) for its Cytisinicline.The voucher is only available to nine programs in the program’s inaugural year. The program, announced in June, aims to reduce FDA assessment times to one to two months from the standard 10 to 12 months.Achieve Life Sciences’ Cytisinicline is indicated for nicotine e-cigarette or vaping cessation. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/17/3168544/0/en/Achieve-Life-Sciences-Receives-FDA-Commissioner-s-National-Priority-Voucher-for-Cytisinicline-for-Treatment-of-Nicotine-Dependence-for-E-cigarette-or-Vaping-Cessation.html">said</a>.In a mid-stage trial, participants treated with Cytisinicline were found to be 2.6 times more likely to quit using nicotine e-cigarettes or vapes compared to placebo. The FDA has agreed on a late-stage trial design that, together with the mid-stage data, would support an application for approval in vaping cessation.In September, the FDA accepted the company’s application for Cytisinicline as a treatment for smoking cessation. The agency is expected to decide on the application by June 20, 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_1_41_17_PM_png_6eea8f50e0.webp" alt="ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ACHV's Sentiment Meter and Message Volume as of 1:41 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>Other drugs awarded the voucher under the FDA program include Merck Group’s infertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy Teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and more.ACHV stock is up by 15% this year and down by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kezar-life-sciences-stock-hit-with-downgrades-price-target-cuts/ch6sK5FR38U">Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a 13 year old schoolboy holds single-use Vapes for Recycling in Kingston on Thames, England. (Photo by Peter Dazeley/Getty Images)

Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.

Equity

The program, announced in June, aims to reduce the time taken for FDA assessments from the standard 10 to 12 months to one to two months.


Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Achieve Life Sciences: Strong Buy Rating on ORCA-OL Trial Progress and FDA Breakthrough Designation

JonesTrading analyst Justin Walsh has reiterated their bullish stance on ACHV stock, giving a Buy rating today. Justin Walsh has given his Buy rati...

Achieve Life Sciences (NASDAQ:ACHV) Given Outperform Rating at Oppenheimer

Oppenheimer restated their outperform rating on shares of Achieve Life Sciences (NASDAQ:ACHV - Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently...

Achieve Life Sciences (ACHV, $4.58) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that ACHV's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ACHV stock results show that Achieve Life Sciences beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Achieve Life Sciences Inc.

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

Current Price	$3.97
Prev Close	$3.96
Open	$4.02
Dividend Yield	0.00%
50-Day Moving Average	$3.95
Beta	1.13
Avg. Volume	2.17M
PE Ratio	-2.88

52-Week High	$5.78
52-Week Low	$1.84
Market Capitalization	$210.81M
EPS (Annual)	-$1.24
Price to Book	6.24
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACHV News

ACHVAchieve Life Sciences Inc.